<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25085" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methylphenidate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Verghese</surname>
            <given-names>Corinne</given-names>
          </name>
          <aff>Ross University/Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Corinne Verghese declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25085.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Methylphenidate is FDA-approved for the treatment of ADHD in adults and children 6 years and older. Additionally, methylphenidate serves as a second-line therapy for narcolepsy in adults. Off-label uses include cancer-related fatigue, refractory depression in older adults, apathy in patients with Alzheimer disease, and cognitive enhancement (eg, memory improvement); the efficacy of methylphenidate for these conditions is moderate at best.</p>
        <p>This activity reviews the mechanism of action, adverse event profile, toxicity, pharmacology, and monitoring parameters associated with methylphenidate therapy. Special attention is given to drug interactions and the importance of proper oversight to prevent misuse. Additional emphasis is placed on the role of the interprofessional healthcare team in optimizing therapy outcomes when treating patients prescribed methylphenidate.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of methylphenidate.</p></list-item><list-item><p>Identify the FDA-approved and off-label uses of methylphenidate.</p></list-item><list-item><p>Assess the contraindications and adverse events associated with methylphenidate administration.</p></list-item><list-item><p>Develop&#x000a0;interprofessional team strategies for improving care coordination and communication so that methylphenidate can be&#x000a0;appropriately administered&#x000a0;to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25085&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25085">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25085.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Methylphenidate is approved by the United States Food and Drug Administration (FDA) for treating attention deficit hyperactivity disorder (ADHD) in children and adults and&#x000a0;as a second-line treatment for&#x000a0;narcolepsy in adults.<xref ref-type="bibr" rid="article-25085.r1">[1]</xref><xref ref-type="bibr" rid="article-25085.r2">[2]</xref>&#x000a0;Children receiving this medication should be 6 years or older.&#x000a0;Methylphenidate&#x000a0;therapy for patients with ADHD and narcolepsy&#x000a0;leads to significantly better outcomes when&#x000a0;supplemented&#x000a0;with nonpharmacologic therapies (ie, social skills training&#x000a0;for ADHD or sleep hygiene measures&#x000a0;for narcolepsy).</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Off-label uses of methylphenidate include treating fatigue in patients with cancer, refractory depression in older adults, apathy in Alzheimer disease, and enhancing cognitive performance (eg, memory).<xref ref-type="bibr" rid="article-25085.r3">[3]</xref><xref ref-type="bibr" rid="article-25085.r4">[4]</xref><xref ref-type="bibr" rid="article-25085.r5">[5]</xref><xref ref-type="bibr" rid="article-25085.r6">[6]</xref><xref ref-type="bibr" rid="article-25085.r7">[7]</xref><xref ref-type="bibr" rid="article-25085.r8">[8]</xref> Since&#x000a0;methylphenidate's cognitive enhancement properties present a potential risk for abuse and addiction,&#x000a0;the Drug Enforcement Administration (DEA) has classified this medication as a&#x000a0;Schedule II substance under the Controlled Substance Act (CSA). The efficacy of methylphenidate for its off-label uses&#x000a0;ranges from limited to moderate. Most of these relatively newer uses are currently being studied and implemented in&#x000a0;clinical practice.</p>
      </sec>
      <sec id="article-25085.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Methylphenidate is&#x000a0;chemically derived from phenethylamine and benzylpiperazine. This medication blocks the reuptake of the neurotransmitters norepinephrine (NE) and dopamine in presynaptic neurons&#x000a0;while inhibiting the transport of these neurotransmitters, increasing the concentration of dopamine and NE in the synaptic cleft.<xref ref-type="bibr" rid="article-25085.r9">[9]</xref> This creates&#x000a0;the classic stimulant effect within the central nervous system (CNS),&#x000a0;primarily in the prefrontal cortex.&#x000a0;Methylphenidate undergoes metabolism&#x000a0;to ritalinic acid&#x000a0;in the liver through de-esterification via carboxylesterase 1 (CES1A1). Compared to other phenethylamine derivatives (eg, amphetamines), methylphenidate appears to increase the firing rate of neurons.<xref ref-type="bibr" rid="article-25085.r10">[10]</xref>&#x000a0;Methylphenidate is also a weak agonist at the serotonin 1A receptor (5HT1A), an additional mechanism contributing to the increased dopamine levels.<xref ref-type="bibr" rid="article-25085.r11">[11]</xref></p>
        <p>Given its effect on&#x000a0;dopamine levels in the synapse, methylphenidate can provide neuroprotection in conditions like Parkinson disease, which involves the loss of dopaminergic neurons, and methamphetamine abuse.<xref ref-type="bibr" rid="article-25085.r12">[12]</xref> This effect results from&#x000a0;direct inhibition of the dopamine transporter and indirect regulation of the vesicular monoamine transporter 2 (VMAT2). The combined interactions reduce the amount of dopamine that accumulates within the cytoplasm, preventing the formation of toxic reactive oxygen species in the brain.</p>
        <p>
<bold>Dependence</bold>
</p>
        <p>The therapeutic dosages for ADHD or narcolepsy that clinicians prescribe are not harmful enough to activate the reward system within the CNS, which centers around the nucleus accumbens. However, excessively higher dosages lead to an overexpression of &#x00394;FosB (a transcriptional activator) in specific neurons within the striatum. The accumulation of &#x00394;FosB in the nucleus accumbens activates a series of signaling cascades that further&#x000a0;contribute to&#x000a0;the addiction mechanism.<xref ref-type="bibr" rid="article-25085.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Slow but extensive; the relative bioavailability for extended-release tablets is 105% in children and 101% in adults (versus immediate-release tablets); the absolute oral bioavailability for&#x000a0;extended-release capsules in children&#x000a0;is 22% and 5% for d-methylphenidate and l-methylphenidate, respectively.&#x000a0;The time of peak plasma concentration is 1.9 hours for&#x000a0;immediate-release tablets and 4.7 hours for&#x000a0;extended-release tablets. When taken with food, the total exposure and peak plasma concentration of methylphenidate are increased; the time for peak plasma concentration&#x000a0;of extended-release tablets is reduced. The effect of alcohol was determined during an in vitro study: 98% of the drug&#x000a0;contained in a 40 mg&#x000a0;extended-release capsule was released in an alcohol concentration of 40%.</p>
        <p><bold>Distribution:</bold> The volume of distribution was 2.65 and 1.80 L/kg for d-methylphenidate and l-methylphenidate, respectively. Methylphenidate's plasma protein binding ranges from 10% to 33%.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Methylphenidate is&#x000a0;primarily metabolized by de-esterification to ritalinic acid, which is pharmacologically inactive.</p>
        <p><bold>Elimination:</bold> Most of the drug (78% to 97%) is&#x000a0;excreted in the urine, while small amounts are excreted in feces.</p>
      </sec>
      <sec id="article-25085.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>For medical&#x000a0;purposes, methylphenidate is typically given orally&#x000a0;and less commonly as a transdermal patch. Multiple oral formulations are available that are categorized&#x000a0;according to how quickly the drug is released: immediate (IR), extended (XR or ER), and sustained.&#x000a0;Various&#x000a0;methylphenidate&#x000a0;formulations are distributed using&#x000a0;the&#x000a0;ER sphenoidal oral drug absorption system with bimodal release and the osmotic (ie, controlled) release delivery system. Chewable tablets (IR or ER) for children and an IR solution are also available.</p>
        <p>If using the transdermal patch, the patient must be aware of placing the patch on the opposite hip each time to achieve its full effect. Those who misuse methylphenidate for recreational purposes prefer to use the intravenous (IV) or intranasal route. Clinicians should assess the risk of abuse before prescribing methylphenidate in any form.</p>
        <p>Methylphenidate is available as a solution, dermal patch, and tablet or capsule (immediate-release, extended-release, or chewable) in the following dosage strengths:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chewable tablets: 2.5 mg, 5 mg, and 10 mg</p>
          </list-item>
          <list-item>
            <p>Orally disintegrating tablets: 8.6 mg, 13.7 mg, and 25.9 mg</p>
          </list-item>
          <list-item>
            <p>Immediate-release tablets: 5 mg, 10 mg, and 20 mg</p>
          </list-item>
          <list-item>
            <p>Extended-release tablets:&#x000a0;10 mg, 20 mg,&#x000a0;18 mg, 27 mg, 36mg, 54 mg, and 72 mg</p>
          </list-item>
          <list-item>
            <p>Extended-release capsules: 10 mg, 20 mg, 30 mg, and 40 mg</p>
          </list-item>
          <list-item>
            <p>Extended-release capsules CD:&#x000a0;10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg</p>
          </list-item>
          <list-item>
            <p>Solution: 5 mg/5 mL and 10 mg/5 mL (in 500 mL bottle)</p>
          </list-item>
          <list-item>
            <p>Patch: 10 mg, 15 mg, 20 mg, and 30 mg (nominal dose over 9 hours)&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Adult and Pediatric Dosage</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Attention deficit disorder (ADD) in adults and pediatric patients (6 years and older) and for narcolepsy
<list list-type="bullet"><list-item><p>Chewable tablets: 2.5 mg, 5 mg, and 10 mg</p></list-item><list-item><p>Immediate-release tablets: 5 mg, 10 mg, and 20 mg</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ADHD in adults and pediatric patients (6 and older) and for narcolepsy
<list list-type="bullet"><list-item><p>Immediate-release tablets: 5 mg, 10 mg, and 20 mg</p></list-item><list-item><p>Extended-release tablets:&#x000a0;10 mg, 20 mg,&#x000a0;18 mg, 27 mg, 36 mg, 54 mg, and 72 mg</p></list-item><list-item><p>Extended-release tablets (24 hours): 18 mg, 27 mg, 36 mg, and&#x000a0;54 mg</p></list-item><list-item><p>Extended-release capsules: 10 mg, 20 mg, 30 mg, and 40 mg</p></list-item><list-item><p>Extended-release capsules CD:&#x000a0;10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg</p></list-item><list-item><p>Solution: 5 mg/5 mL and 10 mg/5 mL in 500 mL bottle</p></list-item><list-item><p>ADHD in adults and pediatric patients (6 years and older) as well as for narcolepsy</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ADHD in pediatric patients (aged 6 to 17 years)
<list list-type="bullet"><list-item><p>Orally disintegrating tablets: 8.6 mg, 13.7 mg, and 25.9 mg</p></list-item><list-item><p>Patch: 10 mg, 15 mg, 20 mg, and 30 mg (nominal dose over 9 hours)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Attention-Deficit Hyperactivity Disorder (ADHD)</bold>
</p>
        <p>Due to&#x000a0;pharmacokinetic differences, many products are not bioequivalent and cannot be exchanged on a mg-for-mg basis.</p>
        <p><bold>Immediate-release (short-acting):</bold> These products include chewable tablets, Ritalin tablets, and Methylin oral solution.&#x000a0;Therapy should be initiated&#x000a0;at 10 to 20 mg daily, divided into&#x000a0;2 doses before breakfast and lunch. Based on&#x000a0;patient response, doses may be increased by 5 to 10 mg weekly or longer intervals, up to a maximum of 60 mg per day, divided into 2 to 3 doses.</p>
        <p><bold>Extended-release (intermediate-acting):</bold> These products include methylphenidate ER tablets (AB-rated generics to&#x000a0;Metadate ER or Methylin ER). Therapy should be initiated with a dose of 10 mg twice&#x000a0;daily. Based on patient response, doses may be increased in increments of 10 mg weekly or longer intervals, up to a maximum of 60 mg daily, divided into&#x000a0;2 doses.</p>
        <p>
<bold>Extended-release and transdermal (long-acting):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adhansia XR&#x000a0;capsules:&#x000a0;Initiate with 25 mg orally once daily in the morning. Doses may be increased in increments of 10 to 15 mg at 5 days or longer intervals, up to a maximum of 100 mg per day. Doses exceeding 85 mg are&#x000a0;associated with&#x000a0;a higher rate of adverse effects.</p>
          </list-item>
          <list-item>
            <p>Aptensio XR capsules:&#x000a0;Initiate with 10 mg orally once daily in the morning. Doses may be increased in increments of 10 mg weekly or longer intervals, up to a maximum of 60 mg daily.</p>
          </list-item>
          <list-item>
            <p>Concerta and Relexxii tablets:&#x000a0;Initiate therapy with 18 to 36 mg once daily in the morning. Doses may be increased in increments of&#x000a0;18 mg weekly or longer intervals, up to a maximum of 72 mg daily.</p>
          </list-item>
          <list-item>
            <p>Jornay PM capsules<bold>:</bold>&#x000a0;Initiate with 20 mg once daily in the evening within 3 hours of&#x000a0;bedtime. Based on response, doses may be increased in increments of 20 mg at weekly or longer intervals, up to a maximum of 100 mg per day.</p>
          </list-item>
          <list-item>
            <p>Metadate CD capsules, QuilliChew ER chewable tablets, and Quillivant XR oral suspension:&#x000a0;Initiate therapy with 20 mg once daily in the morning. Based on response, doses may be increased in increments of 10 to 20 mg at weekly or longer intervals, up to 60 mg daily.</p>
          </list-item>
        </list>
        <p><bold>Transdermal (long-acting):&#x000a0;</bold>These products include the Daytrana&#x000a0;transdermal patch. A 10 mg patch is applied to the hip once daily and&#x000a0;removed 9 hours later.&#x000a0;Absorption may take up to 2 hours before the patient experiences the desired effect. Based on&#x000a0;response, 1 patch may be added at weekly or longer intervals, up to a daily maximum of 30 mg (3 patches). Some patients may&#x000a0;require up to 60 mg daily for optimal efficacy, but a physician should be consulted before exceeding the recommended maximum dose of 30 mg. The patch can be removed before 9 hours if a shorter duration of action is desired or if late-day side effects occur. Alternatively,&#x000a0;the patch can be worn for up to 16 hours if a longer duration of effect is required. Plasma concentrations typically decline once the patch is removed, but drug absorption may continue for several hours afterward.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> The manufacturer label does not provide dose adjustment guidance for patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> The manufacturer label does not provide dose adjustment guidance for patients with&#x000a0;renal impairment. However, most of the drug and its metabolites are excreted in the urine.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Methylphenidate is a pregnancy category C medicine. Various studies have examined methylphenidate&#x000a0;during pregnancy to treat ADHD and narcolepsy. The results of these studies have been inconclusive, so the medication should be administered to pregnant women with caution.<xref ref-type="bibr" rid="article-25085.r14">[14]</xref><xref ref-type="bibr" rid="article-25085.r15">[15]</xref><xref ref-type="bibr" rid="article-25085.r16">[16]</xref><xref ref-type="bibr" rid="article-25085.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Clinicians should monitor and&#x000a0;maintain the relative infant dose below 10% while administering methylphenidate to nursing mothers, as the drug is present in breast milk.<xref ref-type="bibr" rid="article-25085.r18">[18]</xref><xref ref-type="bibr" rid="article-25085.r19">[19]</xref></p>
        <p><bold>Pediatric patients:</bold> Multiple dosage forms and strengths are available for&#x000a0;children&#x000a0;aged 6 to 17.&#x000a0;The AAP considers methylphenidate IR the drug of choice for pediatric patients (3 to 5 years old) when pharmacological treatment is necessary.<xref ref-type="bibr" rid="article-25085.r20">[20]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate release (short-acting) (chewable tablets, Ritalin tablets, and Methylin oral solution):&#x000a0;The recommended starting dose is 5 mg orally twice daily before breakfast and lunch, ideally 30 to 45 minutes before meals. Gradually increase the dosage in increments of 5 to 10 mg each week. A daily dose above 60 mg is not advised.</p>
          </list-item>
          <list-item>
            <p>Extended-release (intermediate-acting) (AB-rated generics to&#x000a0;Metadate ER or Methylin ER):&#x000a0;The recommended starting dose is&#x000a0;10 mg twice daily. Based on tolerability and response, doses may be increased in increments of 10 mg weekly or longer intervals, up to a maximum of 60 mg daily, divided into&#x000a0;2 doses.</p>
          </list-item>
          <list-item>
            <p>Extended-release (long-acting):&#x000a0;
<list list-type="bullet"><list-item><p>Adhansia XR&#x000a0;capsules: Start with 25 mg orally once daily in the morning. Based on tolerability and response, doses may be increased in increments of 10 to 15 mg at 5 days or longer intervals, up to a maximum of 100 mg per day. Doses of more than 85 mg are related to a higher rate of adverse effects.</p></list-item><list-item><p>Aptensio XR capsules: Start with 10 mg orally once daily in the morning. Based on tolerability and response, doses may be increased in increments of 10 mg weekly or longer intervals, up to a maximum of 60 mg daily.</p></list-item><list-item><p>Concerta and Relexxii tablets:&#x000a0;Start with 18 to 36 mg once daily in the morning. Based on tolerability and response, doses may be increased in increments of&#x000a0;18 mg weekly or longer intervals, up to a maximum of 72 mg per day.</p></list-item><list-item><p>Jornay PM capsules:&#x000a0;Start 20 mg once daily in the evening between 6:30 PM and 9:30 PM. Based on tolerability and response, doses may be increased in increments of 20 mg at weekly or longer intervals, up to a maximum of 100 mg per day.</p></list-item><list-item><p>Metadate CD capsules, QuilliChew ER chewable tablets, and Quillivant XR oral suspension: Start with 20 mg once daily in the morning. Based on tolerability and response, doses may be increased in increments of 10 to 20 mg at weekly or longer intervals, up to 60 mg daily.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Transdermal (long-acting): These products include the Daytrana&#x000a0;transdermal patch. One 10 mg patch is applied to the hip once daily, 2 hours before the desired effect, and removed 9 hours after placement. Based on tolerability and response, 1 patch may be added at weekly or longer intervals, up to a maximum of 30 mg per day.&#x000a0;Some patients may need up to 60 mg per day for optimal efficacy. The patch can be removed before 9 hours if a shorter duration of action is desired or if late-day side effects occur. Alternatively, it can be worn for up to 16 hours if a longer duration of effect is required. Plasma concentrations typically decline once the patch is removed, but drug absorption may continue for several hours afterward.</p>
          </list-item>
        </list>
        <p><bold>Older patients:</bold>&#x000a0;No specific dose adjustment guidance is available regarding older adults.</p>
      </sec>
      <sec id="article-25085.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Insomnia and nervousness are the most commonly reported adverse effects in patients using methylphenidate.<xref ref-type="bibr" rid="article-25085.r21">[21]</xref>&#x000a0;Growth retardation (reduced height, weight, and bone marrow density) is observed when&#x000a0;prescribed to children long-term.<xref ref-type="bibr" rid="article-25085.r22">[22]</xref>&#x000a0;Other frequent side effects&#x000a0;primarily&#x000a0;involve the CNS (dizziness, headache, tics, restlessness/akathisia), gastrointestinal (nausea/vomiting, dry mouth, decreased appetite, weight loss, abdominal pain), and cardiovascular systems (tachycardia, palpitations). Dermatologically, patients can complain of excessive sweating and ulceration of their digits. Some patients may even develop blurry vision or decreased libido.&#x000a0;While it rarely occurs, priapism is a medical emergency that requires immediate attention.<xref ref-type="bibr" rid="article-25085.r21">[21]</xref>&#x000a0;Patients are more prone to become easily agitated, irritable, or depressed and go through mood swings or lability. While many common side effects can be relieved by adjusting the dosage or avoiding an afternoon or evening dose, some require treatment emergently to prevent complications.</p>
        <p>Sudden death in both children and adults with a pre-existing structural cardiac abnormality has been reported.<xref ref-type="bibr" rid="article-25085.r23">[23]</xref> Stroke and myocardial infarction&#x000a0;also&#x000a0;have been observed in adults. Due to the risk of such fatal side effects, it is advisable to avoid methylphenidate in patients with a structural cardiac abnormality, cardiomyopathy, or arrhythmias.<xref ref-type="bibr" rid="article-25085.r24">[24]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Methylphenidate can inhibit the metabolism of warfarin, phenytoin, tricyclic antidepressants, or selective serotonin reuptake inhibitors and increase plasma concentration.</p>
          </list-item>
          <list-item>
            <p>Methylphenidate may lower the effectiveness of medicines used to treat hypertension; blood pressure should be monitored, and the dosage of the antihypertensive drug should be adjusted as needed.</p>
          </list-item>
          <list-item>
            <p>The concurrent administration of halogenated anesthetics and methylphenidate may enhance the risk of sudden heart rate and blood pressure increases during surgery; methylphenidate should not be administered to patients&#x000a0;receiving&#x000a0;anesthetics on the day of the surgical procedure.</p>
          </list-item>
          <list-item>
            <p>Combined use of risperidone with methylphenidate&#x000a0;may increase the risk of extrapyramidal symptoms (EPS), particularly when there is a change (increase or decrease) in the dosage of either medication.</p>
          </list-item>
          <list-item>
            <p>Patients&#x000a0;receiving&#x000a0;monoamine oxidase inhibitors (MAOIs) should not be administered methylphenidate. A minimum of 14 days after discontinuing MAOIs must elapse before methylphenidate can be considered a safe treatment option to begin due to the risk of hypertensive crisis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25085.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Medical conditions that are not compatible with&#x000a0;methylphenidate&#x000a0;include&#x000a0;glaucoma, severe hypertension, motor tics, Tourette syndrome, or a family history of Tourette syndrome. Any patient who is noticeably anxious, tense, or agitated should receive alternative treatment. However, it can be given cautiously in patients with a history of bipolar disorder or psychosis as long as clinicians are wary of mania or psychotic episodes induced by the medication.<xref ref-type="bibr" rid="article-25085.r12">[12]</xref>&#x000a0;</p>
        <p>Any patient who develops a hypersensitive reaction to methylphenidate or an individual component of a formulation should have the medication immediately discontinued and switch to another pharmacologic agent. Children&#x000a0;younger than 6 should not be prescribed this medication as there are limited studies to prove its safety or benefit, and it&#x000a0;could cause learning impairments.</p>
      </sec>
      <sec id="article-25085.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Since it has the potential risk of abuse, patients receiving methylphenidate should be monitored for signs of dependence and or abuse while on therapy. A complete blood count with differential should be obtained periodically for those on methylphenidate. The&#x000a0;primary&#x000a0;vital signs to record at each visit are blood pressure and heart rate, especially in patients with underlying hypertension, heart failure, a recent MI, or ventricular arrhythmia, as slight elevations can occur with methylphenidate use. Additionally, if a patient complains of cardiac symptoms, such as chest pain, that worsens with exertion or has a near-syncope episode, then a full cardiac workup should be performed.</p>
        <p>Children receiving methylphenidate should have their growth curves closely monitored for a stable progression in height and weight, as this medication is known to suppress&#x000a0;growth when used daily and long-term. The medication should either be readjusted or discontinued if children are not in a healthy percentile on their growth curve.<xref ref-type="bibr" rid="article-25085.r22">[22]</xref>&#x000a0;Clinicians should screen for symptoms of depression, agitation, aggressiveness, new-onset or pre-existing psychosis or mania, and suicidality, as these can be&#x000a0;exacerbated&#x000a0;during treatment initiation. Clinicians should also monitor for signs of intravenous abuse as frank psychotic episodes can develop. Clinicians should look for peripheral vasculitis (digital ulceration)&#x000a0;during physical exams.&#x000a0;</p>
        <p>Controversial evidence exists regarding the potential for methylphenidate to affect seizure threshold.&#x000a0;If seizures develop while being treated with methylphenidate, treatment should immediately stop.<xref ref-type="bibr" rid="article-25085.r25">[25]</xref><xref ref-type="bibr" rid="article-25085.r26">[26]</xref>&#x000a0;Adults should limit their alcohol use while taking methylphenidate as its stimulant action can mask the actual sedative effect caused by alcohol intoxication, possibly inducing severe respiratory depression. Additionally, a patient who&#x000a0;is concurrently on warfarin, phenytoin, tricyclic antidepressants, or selective serotonin reuptake inhibitors should have their drug levels monitored and adjust doses as needed.</p>
      </sec>
      <sec id="article-25085.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present.<xref ref-type="bibr" rid="article-25085.r21">[21]</xref></p>
      </sec>
      <sec id="article-25085.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Gathering a thorough history from the patient (or the patient's legal guardian) regarding their past medical history, current medications, and social history (obtain a developmental history if the patient is a child) is essential. An interprofessional healthcare team consisting of the patient's primary care provider, psychiatrist, nurse practitioners, clinician assistants, social workers, therapists, school teachers,&#x000a0;and pharmacists&#x000a0;should oversee the patient's case. Communication between each healthcare team member is crucial as medication combined with non-pharmacologic treatment measures provide the most long-term success. Evaluation&#x000a0;of adverse effects requires close monitoring at each visit. Educating the patient's legal guardian on the medication and its side effects is crucial if the patient is a child. This interprofessional approach will optimize therapeutic results while limiting adverse events.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Studies have shown that medication alone is not as effective&#x000a0;as when methylphenidate is&#x000a0;combined with non-pharmacologic treatment measures. Patients with ADHD managed on both medication and non-pharmacologic treatments have been shown to have higher self-esteem and social functioning skills versus those untreated. Long-term beneficial effects have been shown in adults with ADHD who continue to take methylphenidate. Further long-term studies are still in progress.<xref ref-type="bibr" rid="article-25085.r27">[27]</xref><xref ref-type="bibr" rid="article-25085.r28">[28]</xref></p>
      </sec>
      <sec id="article-25085.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25085&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25085">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25085/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25085">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25085.s11">
        <title>References</title>
        <ref id="article-25085.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trenque</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Herlem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abou Taam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drame</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate off-label use and safety.</article-title>
            <source>Springerplus</source>
            <year>2014</year>
            <volume>3</volume>
            <fpage>286</fpage>
            <pub-id pub-id-type="pmid">25279275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorpy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hiller</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The Medical and Economic Burden of Narcolepsy: Implications for Managed Care.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>233</fpage>
            <page-range>233-241</page-range>
            <pub-id pub-id-type="pmid">28975007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Theleritis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Siarkos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katirtzoglou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Politis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities.</article-title>
            <source>J Geriatr Psychiatry Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-49</page-range>
            <pub-id pub-id-type="pmid">28248559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escalante</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reuben</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Manzullo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Gonzalez-Angulo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Mendoza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Overman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cleeland</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.</article-title>
            <source>Cancer J</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">24445757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roj&#x000ed;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Centeno</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The use of methylphenidate to relieve fatigue.</article-title>
            <source>Curr Opin Support Palliat Care</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>299</fpage>
            <page-range>299-305</page-range>
            <pub-id pub-id-type="pmid">28885263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kami&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wysoki&#x00144;ska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Surdyka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kieszko</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pakie&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burdan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The problem of fatigue in patients suffering from neoplastic disease.</article-title>
            <source>Contemp Oncol (Pozn)</source>
            <year>2017</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-135</page-range>
            <pub-id pub-id-type="pmid">28947882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavretsky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reinlieb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St Cyr</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siddarth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ercoli</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Senturk</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>172</volume>
            <issue>6</issue>
            <fpage>561</fpage>
            <page-range>561-9</page-range>
            <pub-id pub-id-type="pmid">25677354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilieva</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis.</article-title>
            <source>J Cogn Neurosci</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>1069</fpage>
            <page-range>1069-89</page-range>
            <pub-id pub-id-type="pmid">25591060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capp</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Pearl</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2005</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-31</page-range>
            <pub-id pub-id-type="pmid">15938665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viggiano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vallone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sadile</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling.</article-title>
            <source>Neural Plast</source>
            <year>2004</year>
            <volume>11</volume>
            <issue>1-2</issue>
            <fpage>97</fpage>
            <page-range>97-114</page-range>
            <pub-id pub-id-type="pmid">15303308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>DeVane</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Ramamoorthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.</article-title>
            <source>Pharmazie</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-5</page-range>
            <pub-id pub-id-type="pmid">19322953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahakian</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bruhl</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Killikelly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Savulich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Piercy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hafizi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fernandez-Egea</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suckling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>2015</year>
            <month>Sep</month>
            <day>19</day>
            <volume>370</volume>
            <issue>1677</issue>
            <fpage>20140214</fpage>
            <pub-id pub-id-type="pmid">26240429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teylan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nairn</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Greengard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2009</year>
            <month>Feb</month>
            <day>24</day>
            <volume>106</volume>
            <issue>8</issue>
            <fpage>2915</fpage>
            <page-range>2915-20</page-range>
            <pub-id pub-id-type="pmid">19202072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Management of Attention Deficit Hyperactivity Disorder During Pregnancy.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>495</fpage>
            <page-range>495-509</page-range>
            <pub-id pub-id-type="pmid">30092924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate and pregnancy.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>1083</fpage>
            <pub-id pub-id-type="pmid">24003978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calvo-Ferrandiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peraita-Adrados</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy with cataplexy and pregnancy: a case-control study.</article-title>
            <source>J Sleep Res</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-272</page-range>
            <pub-id pub-id-type="pmid">28568319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurovich-Horvat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kemlink</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>H&#x000f6;gl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Frauscher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ehrmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Geisler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ettenhuber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peraita-Adrados</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lammers</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Van der Heide</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferini-Strambi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Poli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dauvilliers</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jennum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leonthin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mathis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wierzbicka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puertas</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Beitinger</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Arnulf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Riha</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Torm&#x000e1;&#x00161;iov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slonkov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nev&#x00161;&#x000ed;malov&#x000e1;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sonka</surname>
                <given-names>K</given-names>
              </name>
              <collab>European Narcolepsy Network</collab>
            </person-group>
            <article-title>Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies.</article-title>
            <source>J Sleep Res</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-512</page-range>
            <pub-id pub-id-type="pmid">23560595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolea-Alamanac</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate use in pregnancy and lactation: a systematic review of evidence.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-101</page-range>
            <pub-id pub-id-type="pmid">23593966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ornoy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.</article-title>
            <source>Pharm Res</source>
            <year>2018</year>
            <month>Feb</month>
            <day>06</day>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">29411149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Subcommittee on Attention-Deficit/Hyperactivity Disorder</collab>
              <collab>Steering Committee on Quality Improvement and Management</collab>
              <name>
                <surname>Wolraich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>DuPaul</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Earls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Kaplanek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reiff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>1007</fpage>
            <page-range>1007-22</page-range>
            <pub-id pub-id-type="pmid">22003063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Aleguas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.</article-title>
            <source>CNS Drugs</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>531</fpage>
            <page-range>531-43</page-range>
            <pub-id pub-id-type="pmid">23757186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poulton</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Melzer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-9</page-range>
            <pub-id pub-id-type="pmid">26544899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>ADHD drugs and cardiovascular risk.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Apr</month>
            <day>06</day>
            <volume>354</volume>
            <issue>14</issue>
            <fpage>1445</fpage>
            <page-range>1445-8</page-range>
            <pub-id pub-id-type="pmid">16549404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis.</article-title>
            <source>Eur Child Adolesc Psychiatry</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1283</fpage>
            <page-range>1283-1293</page-range>
            <pub-id pub-id-type="pmid">30143889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Bussing</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cottler</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Winterstein</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-116</page-range>
            <pub-id pub-id-type="pmid">29028437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ickowicz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence.</article-title>
            <source>J Can Acad Child Adolesc Psychiatry</source>
            <year>2016</year>
            <season>Winter</season>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-8</page-range>
            <pub-id pub-id-type="pmid">27047557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harpin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mazzone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raynaud</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kahle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hodgkins</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function.</article-title>
            <source>J Atten Disord</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-305</page-range>
            <pub-id pub-id-type="pmid">23698916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25085.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fredriksen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peleikis</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-31</page-range>
            <pub-id pub-id-type="pmid">26404187</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
